SCHEMBL4090747

SCHEMBL4090747

CCOC(=N)c1ccc2[nH]nc(-c3ccc4cc(OCc5cncn5C)ccc4c3)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTK P33981 6/20 0.40
MAPK8 P45983 4/20 0.40
MAPK1 P28482 4/20 0.39
ITK Q08881 1/20 0.39
MMP2 P08253 1/20 0.38
MMP13 P45452 1/20 0.38
MMP14 P50281 1/20 0.38
NTRK1 P04629 1/20 0.35
DGAT1 O75907 1/20 0.34
LRRK2 Q5S007 2/20 0.34
GPR119 Q8TDV5 1/20 0.34
CYP19A1 P11511 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
MAP2K4 P45985 3/20 0.33
MAPKAPK3 Q16644 3/20 0.33
MAPK6 Q16659 3/20 0.33
MAPKAPK2 P49137 2/20 0.33
MAPKAPK5 Q8IW41 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4083137 0.82 FGFR1 (0.47) TTKMAPK8NTRK1CYP19A1CYP11B1
SCHEMBL4090303 0.81 TBXAS1 (0.48) CYP19A1MEN1ALDH1A1HTTKMT2A
SCHEMBL4050943 0.80 TTK (0.47) TTKMAPK8MAPK1
SCHEMBL4043448 0.80 BTK (0.45) TTKMAPK8MAPK1ITKLRRK2
Hydrochloric Acid SCHEMBL5397824 0.79 BTK (0.44) TTKMAPK8MAPK1ITKLRRK2
Hydrochloric Acid SCHEMBL4083323 0.79 BTK (0.44) TTKMAPK8MAPK1ITKLRRK2
SCHEMBL4039462 0.79 CLK2 (0.51) TTKMAPK8
SCHEMBL4083929 0.79 BTK (0.43) TTKMAPK8MAPK1ITKLRRK2
SCHEMBL4089601 0.78 BRAF (0.44) TTKMAPK8ALDH1A1
SCHEMBL4079832 0.78 TTK (0.43) TTKMAPK8MAPK1DGAT1LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
EP-1692128-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2006-08-23 EP disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed
WO-2005051942-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 TTK 401/4885MAPK8 213/4885MAPK1 171/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 TTK 377/4885MAPK8 201/4885MAPK1 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.